Shares of Johnson Matthey (OTCMKTS:JMPLY) have been given an average rating of “Buy” by the six ratings firms that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $94.00.
A number of equities analysts have recently weighed in on the company. ValuEngine upgraded Johnson Matthey from a “sell” rating to a “hold” rating in a report on Wednesday, January 2nd. Investec lowered Johnson Matthey from a “hold” rating to a “sell” rating in a research report on Friday, April 12th. Finally, Zacks Investment Research raised Johnson Matthey from a “hold” rating to a “buy” rating and set a $94.00 price target on the stock in a research report on Wednesday, April 3rd.
Shares of JMPLY stock remained flat at $$88.56 during trading hours on Friday. The stock had a trading volume of 226 shares, compared to its average volume of 572. Johnson Matthey has a twelve month low of $67.00 and a twelve month high of $102.55. The firm has a market cap of $8.57 billion, a P/E ratio of 16.04, a price-to-earnings-growth ratio of 1.24 and a beta of 1.49.
Johnson Matthey is a global leader in science that enables a cleaner and healthier world. With over 200 years of sustained commitment to innovation and technological breakthroughs, they improve the function, performance and safety of their customers’ products. Their science has a global impact in areas such as low emission transport, pharmaceuticals, chemical processing and making the most efficient use of the planet’s natural resources.
Receive News & Ratings for Johnson Matthey Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson Matthey and related companies with MarketBeat.com's FREE daily email newsletter.